Anti-CD20 in Systemic Lupus Erythematosus

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 31, 2001

Primary Completion Date

January 31, 2006

Study Completion Date

January 31, 2006

Conditions
Lupus Erythematosus, Systemic
Interventions
DRUG

Rituximab

Subjects received four weekly infusions of rituximab at a dose of 375 mg/m\^2

Trial Locations (3)

14623

University of Rochester, Rochester

19104

University of Pennsylvania, Philadelphia

80045

University of Colorado, Denver

All Listed Sponsors
collaborator

Autoimmunity Centers of Excellence

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00036491 - Anti-CD20 in Systemic Lupus Erythematosus | Biotech Hunter | Biotech Hunter